BNP and NT-proBNP for Predicting Heart Complications: Prognostic Biomarker Review

Review of BNP and NT-proBNP as prognostic biomarkers confirms their predictive value for adverse cardiovascular events across multiple clinical settings.

Ammar, Lama A et al.·Heart failure reviews·2025·Strong EvidenceMeta-Analysis
RPEP-09931Meta AnalysisStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Meta-Analysis
Evidence
Strong Evidence
Sample
N=large
Participants
HFpEF patients across observational studies and randomized controlled trials

What This Study Found

Review of BNP and NT-proBNP as prognostic biomarkers confirms their predictive value for adverse cardiovascular events across multiple clinical settings.

Key Numbers

Meta-analysis of studies examining BNP and NT-proBNP as prognostic markers for adverse outcomes, cardiovascular events, and mortality in HFpEF.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Review of BNP and NT-proBNP as prognostic biomarkers confirms their predictive value for adverse car
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
BNP and NT-proBNP as prognostic biomarkers for the prediction of adverse outcomes in HFpEF patients: A systematic review and meta-analysis.
Published In:
Heart failure reviews, 30(1), 45-54 (2025)
Database ID:
RPEP-09931

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Combines results from multiple studies to find an overall pattern.

What do these levels mean? →

Frequently Asked Questions

What does this mean?

Review of BNP and NT-proBNP as prognostic biomarkers confirms their predictive value for adverse cardiovascular events across multiple clinical settings.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09931·https://rethinkpeptides.com/research/RPEP-09931

APA

Ammar, Lama A; Massoud, Gaelle P; Chidiac, Charbel; Booz, George W; Altara, Raffaele; Zouein, Fouad A. (2025). BNP and NT-proBNP as prognostic biomarkers for the prediction of adverse outcomes in HFpEF patients: A systematic review and meta-analysis.. Heart failure reviews, 30(1), 45-54. https://doi.org/10.1007/s10741-024-10442-6

MLA

Ammar, Lama A, et al. "BNP and NT-proBNP as prognostic biomarkers for the prediction of adverse outcomes in HFpEF patients: A systematic review and meta-analysis.." Heart failure reviews, 2025. https://doi.org/10.1007/s10741-024-10442-6

RethinkPeptides

RethinkPeptides Research Database. "BNP and NT-proBNP as prognostic biomarkers for the predictio..." RPEP-09931. Retrieved from https://rethinkpeptides.com/research/ammar-2025-bnp-and-ntprobnp-as

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.